Showing items 1 - 20 of 73

Your selections:

"Pelvic radiation disease": new understanding and new solutions for a new disease in the era of cancer survivorship

Measuring personal and functional changes in prostate cancer survivors: development and validation of the FADE: data from the TROG 03.04 RADAR trial

The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer

Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial

Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer

Validation of prediction models for radiation-induced late rectal bleeding: Evidence from a large pooled population of prostate cancer patients

Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials

Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial

Gleason scoring: a comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

When to choose radiotherapy for prostate cancer, and what technique?

Picking the optimal duration of hormonal therapy in men with high-risk and locally advanced prostate cancer treated with radiotherapy

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial

Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer

It's time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials

Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

The radiotherapeutic injury: a complex 'wound'

  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit